MADRIGAL PHARMACEUTICALS, INC.
About MADRIGAL PHARMACEUTICALS, INC.
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), now referred to as metabolic dysfunction-associated steatohepatitis (MASH). Its lead candidate, resmetirom, is a once daily, oral, thyroid hormone receptor (THR)-ฮฒ selective agonist designed to target key underlying causes of NASH in the liver. The company has conducted public offerings including a $500 million underwritten public offering of common stock.
- ๐ Madrigal Pharmaceuticals Announces Pricing of $500 Million Public Offering | Madrigal Pharmaceuticals, Inc.
- ๐ Delving into the Latest Updates on Madrigal Pharmaceuticals, Inc. with Synapse
- ๐ Madrigal Pharmaceuticals - 2026 Company Profile, Funding, Competitors & Financials - Tracxn
- ๐ madrigal pharmaceuticals, inc.
- ๐ Overview | Madrigal Pharmaceuticals, Inc.
Investors
Not disclosed in the source filing. Form D filings do not list investors โ StreetZero surfaces them from news where available.
Key highlights
- Priced $500 million public offering of common stock
- Lead asset resmetirom is a THR-ฮฒ agonist for MASH with accelerated FDA approval
- Granted equity inducement awards to 20 new employees under 2025 Inducement Plan
- Celebrated 10 years as a NASDAQ-listed public company
Ask StreetZero about MADRIGAL PHARMACEUTICALS, INC.
Put our AI to work on this deal.
Similar companies
Other Public Equity (NASDAQ) deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account